Sharing our knowledge of melanoma on the global stage
15 April 2021
More than 2,000 clinicians and researchers from across the globe will unite online this weekend for the virtual 10th World Congress of Melanoma in conjunction with the 17th EADO Congress.
As leaders in the field of melanoma, many clinicians and researchers from Melanoma Institute Australia (MIA) will be sharing their knowledge as this congress provides an opportunity to educate clinicians on the latest developments in our understanding and treatment of skin cancer.
Here are just a handful of the areas of melanoma research that we will be presenting on:
- Renowned pathologist and MIA’s Co-Medical Director, Prof Richard Scolyer, will discuss how we can predict the likelihood that a patient’s disease will return by examining the molecular profile of their melanoma.
- Medical Oncologist and MIA’s Co-Medical Director Prof Georgina Long AO will be delivering a keynote address discussing if a cure for advanced melanoma is on the horizon. She will review the recent advancements in drug development to treat advanced melanoma, as well as outline the challenges we still face to overcome drug resistance. Prof Long will also highlight the importance of getting our prevention messaging across if we truly want to reach our goal of zero deaths from melanoma.
- Translational researcher Prof Helen Rizos will be reviewing how circulating DNA in the bloodstream can be used as a marker to monitor disease and treatment response in patients with advanced melanoma. This minimally invasive technique can help monitor patients in real-time and is proving to be a valuable new tool to support the clinical care of patients with melanoma.
- Dermatologist Prof Diona Damian will be presenting an overview of nicotinamide (vitamin B3) as a preventative measure to reduce the incidence of non-melanoma skin cancers in high-risk patients.
- Using clinical data alone can help predict which patients will respond well to treatment with immunotherapy. However, when Dr James Wilmott and our team of lab researchers examined biopsies taken from patients before immunotherapy, they found that biopsies showing higher numbers of immune cells touching the melanoma were associated with response and tumour shrinkage. Dr Wilmott will share these findings which will ultimately help select the ideal therapies for patients and will be incorporated into our Personalised Immunotherapy Platform.
Through the combined sharing of knowledge, it is inspiring to see the global commitment to enhancing our understanding of melanoma that will ultimately improve the care of melanoma patients.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.
They are a formidable team - in work and in play
This week, Melanoma Institute Australia hosted the first of six